Use of IL-6 in liver injury
View Patent ↗The invention relates to the use of IL-6 in liver cirrhosis.
1. A method for treating hepatic fibrosis, comprising administering to a patient in need thereof an effective dose of IL-6 or IL-6 fused to another protein or polypeptide, optionally together with a pharmaceutically acceptable carrier to treat hepatic fibrosis, wherein the dose is in the range of 0.1 to 10 mcg/kg weight.
2. The method according to claim 1 , wherein the method of treatment comprises liver resection.
3. The method according to claim 1 , wherein the dose is about 0.1 mcg/kg or about 1 mcg/kg or about 10 mcg/kg.
4. The method according to claim 1 , wherein the IL-6 or IL-6 fused to another protein or polypeptide is administered daily or administered once a week or administered three times per week.
5. The method according to claim 1 , wherein the IL-6 is glycosylated at one or more sites.
6. The method according to claim 1 , wherein the IL-6 is not glycosylated.
7. The method according to claim 1 , wherein the other protein or polypeptide to which IL-6 is fused is an immunoglobulin (Ig) or a fragment thereof.
8. The method according to claim 1 , wherein the other protein or polypeptide to which IL-6 is fused is gp80 or a fragment thereof.
9. The method of claim 1 , wherein the hepatic fibrosis is caused by hepatotoxic agents.
10. A method for treating hepatic fibrosis which comprises resection, comprising administering to a patient in need thereof an effective dose of IL-6, or IL-6 fused to another protein or polypeptide to treat hepatic fibrosis including resection, wherein the dose is in the range of 0.1 to 10 mcg/kg weight.
11. The method according to claim 10 , wherein the administration is carried out before during and/or after resection treatment.
12. The method of claim 10 , wherein the hepatic fibrosis is caused by hepatotoxic agents.
13. The method according to claim 10 , wherein the other protein or polypeptide to which IL-6 is fused is an immunoglobulin (Ig) or a fragment thereof.
14. The method according to claim 10 , wherein the other protein or polypeptide to which IL-6 is fused is gp80 or a fragment thereof.
15. A method for treating hepatic fibrosis followed by engraftment, comprising administering to a patient in need thereof an effective dose of IL-6, or IL-6 fused to another protein or polypeptide to treat hepatic fibrosis, wherein the dose is in the range of 0.1 to 10 mcg/kg weight.
16. The method of claim 15 , wherein the hepatic fibrosis is caused by hepatotoxic agents.
17. The method according to claim 15 , wherein the other protein or polypeptide to which IL-6 is fused is an immunoglobulin (Ig) or a fragment thereof.
18. The method according to claim 15 , wherein the other protein or polypeptide to which IL-6 is fused is gp80 or a fragment thereof.